- Subjects receiving the 2.5 mg dose of EB613 showed significant dose-related increases in BMD at the lumbar spine, total hip, and femoral neck at 6 months
- Subjects receiving the 2.5 mg dose of EB613 for 6 months had a significant placebo adjusted increase of 3.78% in lumbar spine BMD (p
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
Watch Entera Bio's latest callEntera Bio (NASDAQ:ENTX) Q1 2022 Earnings Call · Replay · May 18, 2022Read the transcript of Entera Bio (NASDAQ:ENTX) Q1 2022 Earnings CallEarlier from Entera Bio
- Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union
- Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates
- Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors
- Entera Appoints Ramesh Ratan as Chief Financial Officer
- New Data Suggest Entera’s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress
Later from Entera Bio
- Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
- Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting
- Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021
- Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates
- Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021
Follow Entera Bio into a list and get an email when it puts out news.
Follow Entera Bio